dMMR

About

Biomarker Type: Mismatch Repair

Present: True

Status: Deficient


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR Non-Small Cell Lung Cancer Cemiplimab
Sensitivity (+) dMMR Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
Sensitivity (+) dMMR Endometrial Carcinoma Dostarlimab
Sensitivity (+) dMMR Any solid tumor Dostarlimab
Sensitivity (+) dMMR Endometrial Carcinoma Carboplatin, Durvalumab, Paclitaxel
Sensitivity (+) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab
Sensitivity (+) dMMR Any solid tumor Pembrolizumab
Sensitivity (+) dMMR Colorectal Adenocarcinoma Pembrolizumab
Sensitivity (+) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab
Sensitivity (+) dMMR Colorectal Adenocarcinoma Nivolumab
Sensitivity (+) dMMR Endometrial Carcinoma Carboplatin, Durvalumab, Paclitaxel
Sensitivity (+) dMMR Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
Sensitivity (+) dMMR Endometrial Carcinoma Dostarlimab
Sensitivity (+) dMMR Colorectal Adenocarcinoma Pembrolizumab
Sensitivity (+) dMMR Endometrial Carcinoma Pembrolizumab
Sensitivity (+) dMMR Esophagogastric Adenocarcinoma Pembrolizumab
Sensitivity (+) dMMR Gastrointestinal Stromal Tumor Pembrolizumab
Sensitivity (+) dMMR Cholangiocarcinoma Pembrolizumab
Sensitivity (+) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab
Sensitivity (+) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab
Sensitivity (+) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab
Sensitivity (+) dMMR Colorectal Adenocarcinoma Pembrolizumab